TRX Biosciences
- Company typePrivate
- Founded2021
- HeadquartersBabraham, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What TRX Biosciences does
TRx Biosciences Limited is a UK-based, privately held pharmaceutical technology company founded in 2020 and headquartered at the Babraham Research Campus in Cambridge. The company has developed LipiCore™, a proprietary lipid-based oral drug delivery platform that exploits chylomicron-mediated uptake and unutilised transport channels to deliver small molecules and peptides to specific organs, cells and tissues while avoiding first-pass metabolism. LipiCore is positioned to address bioavailability, solubility and permeability constraints simultaneously and has demonstrated CNS penetration (drug detected in cerebrospinal fluid) and tumour uptake in early human studies.
The company operates a dual-track business model: (i) co-development and licensing partnerships with pharmaceutical companies — current partners include Oxilio (oncology, OXL001), Mandarapharma (cannabinoid CNS therapies), Monument Therapeutics (neuroinflammation, MT1980) and Arecor (oral GLP-1) — under which TRx receives upfront fees, development milestones and royalties; and (ii) a wholly-owned pipeline of four preclinical assets (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, TRX-914 for depression) intended for out-licensing following clinical validation. Two co-development programmes (OXL001 and MT1980) have reported positive Phase 1 data in 2023, and a March 2024 collaboration with Arecor extends the platform into the oral peptide/GLP-1 opportunity.
The company is led by repeat biotech entrepreneurs Dr Robin Bannister (CEO; prior exits include Seebri and Arakis) and John Brew (CSO; brought Flarin to market), with advisor Dr Andy Richards CBE. TRx is funded by private life sciences specialists through a seed round completed in October 2021; no subsequent financing events are disclosed. Foundation IP for the biodistribution platform was filed in March 2021, with protection extending to at least 2041.
TRX Biosciences firmographics
Firmographics- Name
- TRX Biosciences
- Legal name
- TRx Biosciences Limited
- Website
- https://trxbiosciences.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TRX Biosciences industry classification
Industry- Product category
- Pharmaceutical Drug Delivery Technology
- NAICS
- Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where TRX Biosciences is headquartered
LocationHeadquarters
- HQ city
- Babraham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
TRX Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Technology Licensing & Co-development: TRx licenses its oral delivery technology to pharmaceutical partners. Partners pay upfront fees, milestone payments tied to development progress, and ongoing royalties as products advance through clinical development and commercialisation.
- Wholly-Owned Pipeline Development: TRx develops its own proprietary product pipeline (TRX-611 for IBD, TRX-813 for Cancer, TRX-712 for COPD, TRX-914 for Depression) with the intent to out-license at optimal value following clinical validation.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
TRX Biosciences product offering
Product offeringCore offering
TRx Biosciences licenses its LipiCore™ lipid-based oral drug delivery platform to pharmaceutical partners to enable targeted oral delivery of small molecule drugs and peptides to specific organs, cells, and tissues. The technology exploits unexploited uptake channels and chylomicron-based transport to bypass first-pass metabolism and enhance uptake in brain and tumours. Alongside partnerships, the company develops and intends to out-license a wholly-owned pipeline covering CNS, cancer, respiratory, and inflammatory indications.
Product overview
TRX Biosciences offers a proprietary oral drug delivery technology platform called LipiCore™ that enables targeted delivery of small molecule drugs to specific organs, cells, and tissues, particularly the brain, tumors, and immune system. The technology addresses bioavailability, solubility, and permeability limitations while reducing first-pass metabolism. TRX is building both a co-development pipeline with partners (including MT1980 with Monument Therapeutics for neuroinflammation and OXL001 with Oxilio for cancer) and a wholly-owned product portfolio (TRX-611 for IBD, TRX-813 for cancer, TRX-712 for COPD, and TRX-914 for depression). The company operates through strategic partnerships while developing its own pipeline following successful technology validation.
Differentiator
Problem solved
Functional benefit
Brands
- LipiCore™: TRx's proprietary oral delivery technology platform for targeted drug delivery using lipid technology.
Products and services
- LipiCore™ Oral Delivery Technology Proprietary lipid-based oral drug delivery technology platform licensed to pharmaceutical and biotech partners. Enables targeted delivery of small molecule drugs and peptides to specific organs, cells, and tissues, including brain and tumours, by exploiting unexploited uptake channels and chylomicron-based transport while avoiding first-pass metabolism.
- TRX-611 Wholly-owned pipeline product for inflammatory bowel disease (IBD) using a novel approach to modulating the anti-inflammatory response via LipiCore™.
- TRX-813 Wholly-owned pipeline product for cancer, involving reprofiling of a poorly absorbed anthelmintic with tumour targeting capabilities enabled by LipiCore™.
- TRX-712 Wholly-owned pipeline product for chronic obstructive pulmonary disease (COPD) using preferential lung delivery of unexploited anti-inflammatory drugs via LipiCore™.
- TRX-914 Wholly-owned pipeline product for depression utilising targeted brain delivery with a proven mechanism of action via LipiCore™.
- MT1980 (Co-development with Monument Therapeutics) Co-development anti-inflammatory compound for neuroinflammation using TRx's brain-targeting LipiCore™ delivery, targeting Alzheimer's disease, post-operative cognitive decline, and long Covid. Demonstrated presence in cerebrospinal fluid in Phase I studies.
- OXL001 (Co-development with Oxilio) Co-development novel lipid-based aprepitant formulation for pan-cancer treatment leveraging TRx's oral targeted delivery technology. Achieved dose-proportional plasma exposures in Phase 1 studies.
Companies that use TRX Biosciences
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
TRX Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TRX Biosciences partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Arecor TherapeuticscoreResearch collaboration to develop oral GLP-1 receptor agonist product combining TRx's LipiCore™ technology with Arecor's Arestat™ formulation platform. Aimed at overcoming oral peptide delivery challenges for diabetes and obesity treatment in a market predicted to reach $80-$100+ billion by 2030. Collaboration scope for expansion to additional oral peptide products.
- Quotient SciencesminorDevelopment partner providing Translational Pharmaceutics® platform and clinical study facilities for Oxilio's OXL001 Phase 1 study. Quotient Sciences conducted the clinical assessments enabling accelerated development timelines.
- Monument TherapeuticscoreExclusive technology licensing and development partnership for MT1980 neuroinflammation programme. TRx technology solves pharmacokinetics and blood-brain barrier penetration issues. First-in-human Phase 1 study demonstrated drug presence in cerebrospinal fluid. TRx receives upfront payments and royalties with opportunity to broaden across Monument's portfolio.
- MandarapharmacoreResearch agreement for cannabinoid therapy development targeting anxiety, depression, PTSD, and traumatic brain injury. TRx technology addresses oral delivery challenges and first-pass metabolism while enabling brain targeting. Partnership opportunity to expand across multiple Mandara development programmes.
- Oxilio LimitedcoreResearch agreement for OXL001, a novel pan-cancer treatment. TRx technology addresses bioavailability and pharmacokinetic challenges while enhancing tumour uptake. TRx receives upfront, milestone, and royalty payments as Oxilio progresses development. Phase 1 study completed successfully in 2023 showing safe, dose-proportional plasma exposures.
Scale indicators2 records
Recent moves7 records
Expansion highlights5 records
TRX Biosciences competitors and assessment
Company assessmentBroad incumbents
- Halozyme Therapeutics: Platform drug delivery company monetising its ENHANZE technology through royalty-bearing licensing deals with multiple pharma partners. A directly analogous business model to TRx (proprietary delivery IP, partner-led development, royalty stream).
- Catalent: Large CDMO with broad drug delivery, oral formulation, softgel and biologic capabilities. Catalent competes for the same partners and same oral/specialised formulation deals that TRx pursues, but operates across many dosage forms and therapeutic areas rather than TRx's targeted-delivery niche.
- Lonza Group: Global CDMO with active interest in oral biologics and bioavailability enhancement collaborations. Comparable to TRx as a broad drug-delivery platform and partner of choice for pharma companies needing formulation and process IP.
- Vectura Group: Established inhalation and lung drug delivery platform company. Vectura's focus on preferential lung delivery and reformulation of small molecules overlaps with TRx's lung-targeted anti-inflammatory pipeline (TRX-712 COPD) and from-founder heritage (Andy Richards advised Vectura at similar stage).
Direct peers
- Quotient Sciences: Translational Pharmaceutics platform provider offering drug formulation development and clinical testing in an integrated service. Quotient conducted the OXL001 Phase 1 study under TRx's partnership, making it a current operational collaborator and a direct peer in accelerating oral drug formulations to first-in-human and clinical proof-of-concept.
- Monument Therapeutics: Stratified neuroscience company partnered with TRx to apply LipiCore to its MT1980 neuroinflammation programme. Demonstrates TRx's customer-of-TRx archetype (a small clinical-stage CNS biotech that adopts TRx tech), making it a peer from a customer-relationship perspective.
- Arecor Therapeutics: UK-based formulation technology company developing novel therapeutic products including oral peptides. Arecor is both a direct co-development partner of TRx (oral GLP-1 collaboration, March 2024) and a direct functional peer in lipid/excipient-driven drug delivery and reformulation of biologics and peptides for enhanced bioavailability.
Emerging players
- Diabetology Limited: Clinical-stage company developing oral formulations of peptides/metformin-class drugs. Operates in overlapping oral peptide/bioavailability space that TRx is pursuing via the Arecor collaboration and other partnerships.
- Enteris BioPharma: Specialised oral peptide and small molecule formulation company with proprietary delivery technologies. Targets many of the same bioavailability and permeability problems (including oral peptides) that TRx's LipiCore addresses, putting it in the same emerging oral delivery platform cohort.
- Noxxon Pharma: Clinical-stage biotech using platform chemistry to enable delivery of difficult-to-formulate therapeutics, including CNS indications. Operates in a similar niche of solving formulation/targeting bottlenecks that limit small molecule and biologic pharmacology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
TRX Biosciences social profiles
Digital presenceTRX Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
TRX Biosciences leadership team
Management profileNumber of profiles
TRX Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TRX Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TRX Biosciences
What does TRX Biosciences do?
TRx Biosciences licenses its LipiCore™ lipid-based oral drug delivery platform to pharmaceutical partners to enable targeted oral delivery of small molecule drugs and peptides to specific organs, cells, and tissues. The technology exploits unexploited uptake channels and chylomicron-based transport to bypass first-pass metabolism and enhance uptake in brain and tumours. Alongside partnerships, the company develops and intends to out-license a wholly-owned pipeline covering CNS, cancer, respiratory, and inflammatory indications.
Is TRX Biosciences a public or private company?
TRX Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was TRX Biosciences founded?
TRX Biosciences was founded in 2021. It employs 1 to 10 people.
Where is TRX Biosciences based?
TRX Biosciences is headquartered in Babraham, United Kingdom, in the Europe region.
How does TRX Biosciences make money?
Two revenue lines are on record. Technology Licensing & Co-development is the primary driver. The others are wholly-Owned Pipeline Development.
Who are TRX Biosciences's main competitors?
Broad incumbents on record are Halozyme Therapeutics, Catalent, Lonza Group and Vectura Group. Direct peers are Quotient Sciences, Monument Therapeutics and Arecor Therapeutics. Emerging players are Diabetology Limited, Enteris BioPharma and Noxxon Pharma.
Does TRX Biosciences have an API?
No public API is recorded for TRX Biosciences.
What industry is TRX Biosciences in?
TRX Biosciences's product category is Pharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 5417 and its SIC code is 2834.